Tarenflurbil
Tarenflurbil
Tarenflurbil (pronounced: tahr-en-flur-bil), also known as Flurizan, is a nonsteroidal anti-inflammatory drug (NSAID) that was investigated for its potential use in the treatment of Alzheimer's disease.
Etymology
The name "Tarenflurbil" is a combination of parts of the chemical name for the drug, which is 2-phenylmethylamino]-5-trifluoromethylphenyl]pentanoic acid.
Usage
Tarenflurbil was developed by Myriad Genetics, a biotechnology company based in the United States. It was designed to reduce the production of amyloid beta peptides, which are believed to be a primary cause of the neurodegeneration seen in Alzheimer's disease. However, in Phase III clinical trials, Tarenflurbil failed to show a significant effect on the progression of Alzheimer's disease, leading to the discontinuation of its development.
Related Terms
- Nonsteroidal anti-inflammatory drug: A class of drugs that provides analgesic and antipyretic effects, and, in higher doses, anti-inflammatory effects.
- Alzheimer's disease: A progressive disease that destroys memory and other important mental functions.
- Amyloid beta: Peptides of 36–43 amino acids that are crucially involved in Alzheimer's disease as the main component of the amyloid plaques found in the brains of Alzheimer patients.
- Myriad Genetics: A publicly traded American molecular diagnostic company based in Salt Lake City, Utah, United States.
External links
- Medical encyclopedia article on Tarenflurbil
- Wikipedia's article - Tarenflurbil
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski